Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0,13c per unit and a final 0,023c per unit that was all i got
The shareholders will benefit from the sale of the MEDI contract and the trodusquemine and Squalamine patents and research. There is good value in all. MEDI may buy back the contract for $10million or $20 million. The contract stipulates that GENR shareholders receive $54million in timeline payments..and 10% royalty from eventual marketing of the IL9 drug.
The vote was no suprise to anyone... and it benefits shareholders who will end up owning all assets.
The shareholders will benefit from the sale of the MEDI contract and the trodusquemine and Squalamine patents and research. There is good value in all. MEDI may buy back the contract for $10million or $20 million. The contract stipulates that GENR shareholders receive $54million in timeline payments..and 10% royalty from eventual marketing of the IL9 drug.
The vote was no suprise to anyone... and it benefits shareholders who will end up owning all assets.
Liquidation approved....What's the value of GENR??
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Monday June 9, 8:00 am ET
PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.
The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.
"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) study later this year."
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Wednesday January 23, 8:00 am ET
- Second filing provides opportunity for additional indications and increased potential market -
PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine (MSI-1436) in type 2 diabetes is now in effect. This application represents the second IND filed by the Company in 2007 for MSI- 1436. A previous IND for the treatment of obesity, under which Genaera is currently conducting phase 1 clinical trials, has been in effect since April 2007. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.
http://biz.yahoo.com/prnews/080123/nyw032.html?.v=101
Stay away from GENR:
Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
PLYMOUTH MEETING, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today the presentation of preclinical data on its Phase 1 product candidate for obesity, trodusquemine (MSI-1436), at the North American Association for the Study of Obesity (NAASO) Annual Meeting in New Orleans, Louisiana.
The poster presentation of preclinical data shows that MSI-1436 demonstrated selective inhibition of PTP-1B but did not inhibit the activities of DDP-IV, TC-PTP or SHP-2 nor inhibit ligand binding to the CB1 or 5HT2C receptors. Additional in vitro testing demonstrated that MSI-1436 does not activate PPAR (alpha, beta/delta or gamma) nor bind to 250 different kinases. In an animal model, MSI-1436 was found to distribute to both the liver and brain upon peripheral administration and was observed to modify the phosphorylation status of downstream effectors of insulin signaling.
The study confirmed that MSI-1436 is a selective inhibitor of PTP-1B, and its central and peripheral effects provide promise for the simultaneous treatment of both type 2 diabetes and obesity.
The poster at NAASO entitled, 'Trodusquemine is a Protein Tyrosine Phosphatase 1B Inhibitor that Causes Differential Weight Loss,' will be presented today from 9:00 a.m. to 2:30 p.m., Central Time. Researchers from Genaera will be at the poster from 1:00 p.m. to 2:30 p.m. to answer any questions.
About Trodusquemine
Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both type 2 diabetes and obesity. By inhibiting PTP-1B, trodusquemine has been shown to decrease appetite and normalize blood sugar as PTB-1B is central to both the insulin and leptin pathways. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment for two of the most serious metabolic diseases, type 2 diabetes and obesity. In addition, trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly selective and reversible inhibitor of PTP-1B. In vitro kinetics demonstrate that trodusquemine is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site of PTP-1B. Data also demonstrate that trodusquemine can produce consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. Trodusquemine suppresses appetite, causes differential weight loss, reduces adipocyte size, reduces body fat (with no reduction of lean mass), and improves glucose tolerance via inhibition of a unique combination of signaling pathways in a mouse model of diet induced obesity (DIO).
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'believe,' 'continue,' 'develop,' 'expect,' 'plan' and 'potential' or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
I would have to agree with you on the MacroChem end, that company was delisted and I thought had gone BK. I wouldn't guess that they even have a million to pay to GENR.
Complete joke of a deal, IMO.
Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
Supports Genaera's Strategic Focus on Core Programs in Obesity and Asthma
PLYMOUTH MEETING, Pa., Oct. 3 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that MacroChem Corporation (OTC Bulletin Board: MACM) has exercised the July 2007 option to acquire from Genaera the exclusive worldwide license rights for use of pexiganan as a drug. Pexiganan is a novel, small peptide anti-infective originally discovered by Genaera scientists which was developed for the treatment of patients with infected diabetic foot ulcers.
Under the terms of the license agreement, MacroChem has agreed to pay Genaera an initial fee of $1 million dollars in several installments through February 1, 2008. The terms of the agreement also include $7 million dollars in milestone payments to Genaera upon the achievement of clinical milestones including the start of phase 3 clinical trials and regulatory approval. The agreement further includes sales-based milestones of up to $35 million dollars, and 10% royalty payments on net sales. In addition, MacroChem will assume all clinical development, manufacturing and regulatory activities for pexiganan.
'We are pleased to enter into this agreement with MacroChem for the therapeutic rights to pexiganan. We believe pexiganan has significant potential to treat infected diabetic foot ulcers and that MacroChem, with its complementary pipeline and focus, is an excellent partner to move pexiganan forward to commercialization,' stated Dr. Henry Wolfe, Executive Vice President and Chief Scientific Officer.
'Out-licensing of pexiganan is an important first step in the execution of Genaera's strategy to divest our non-core assets, which also include squalamine and LOMUCIN(TM), while we aggressively continue to focus our efforts and resources on advancing MSI-1436 (trodusquemine) through the clinic for the treatment of obesity and type 2 diabetes,' stated Jack Armstrong, President and Chief Executive Officer. 'We are pleased to have forged the MacroChem partnership for pexiganan and believe it will result in the drug candidate progressing toward approval, which would benefit both companies. Added to our partnership with MedImmune/Astra Zeneca for the anti-IL-9 antibody (MEDI-528), which is already in multiple phase 2 trials, the MacroChem license provides Genaera with two excellent partnerships and opportunities for the future. Our goal is to achieve the same excellent level of cooperation and communication with MacroChem that characterizes our current relationship with MedImmune.'
About Pexiganan
Pexiganan is a 22-amino acid, linear peptide which is formulated as a cream and has a novel mechanism of action based on its ability to selectively disrupt the integrity of bacterial cell membranes. In addition, it has antimicrobial activity against both Gram positive and Gram negative organisms that commonly infect skin and soft tissue. Pexiganan is also effective against methycillin-resistant staphylococcus aureus (MRSA) and has a low potential for induction of resistance and no cross-resistance with existing therapeutic antibiotics.
Genaera Corporation Announces Second Quarter Financial Results
Thursday August 9, 6:22 pm ET
PLYMOUTH MEETING, Pa., Aug. 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced its financial results for the three- and six-month periods ended June 30, 2007. The net loss for the three- month period ended June 30, 2007 was $2.0 million, or $(0.11) per share basic and diluted, as compared to a net loss of $5.8 million, or $(0.50) per share basic and diluted, for the three-month period ended June 30, 2006. The net loss for the six-month period ended June 30, 2007 was $6.2 million, or $(0.35) per share basic and diluted, as compared to a net loss of $13.1 million, or $(1.14) per share basic and diluted, for the six-month period ended June 30, 2006.
Genaera's research and development expenses for the three- and six-month periods ended June 30, 2007, were $3.1 million and $6.6 million, respectively, compared to $4.6 million and $10.8 million, respectively, for the same periods in 2006. The decrease was primarily due to a decrease in clinical and personnel costs as a result of the discontinuation of the EVIZON(TM) (squalamine lactate) program for the treatment of wet age-related macular degeneration, partially offset by an increase in personnel costs and manufacturing expenses related to the trodusquemine (MSI-1436) program for the treatment of obesity.
Genaera's general and administrative expenses for the three- and six-month periods ended June 30, 2007, were $1.6 million and $3.1 million, respectively, compared to $1.5 million and $3.1 million, respectively, for the same periods in 2006. The increase in the three-month period ended June 30, 2007, was due principally to costs associated with the departure of an executive in the current year.
The Company's cash, cash equivalents and short-term investment balance was $26.3 million at June 30, 2007.
"The second quarter was pivotal for Genaera," said Jack Armstrong, President and Chief Executive Officer of Genaera. "We completed a comprehensive strategic review of our organization and defined a clear strategy to focus resources on our two core assets, MSI-1436 for obesity and type 2 diabetes and the anti-IL-9 asthma program partnered with MedImmune, Inc./Astra Zeneca. We are pleased by the commitment both companies have demonstrated to advance the anti-IL-9 program through the announced initiation of additional planned Phase 2 studies throughout the second half of 2007. During this quarter, we dosed our first patient with MSI-1436 in the first Phase 1 trial (Study 101) in healthy overweight and obese volunteers, and presented exciting preclinical data at the American Diabetes Association. We continue to move MSI-1436 through the clinic and remain on track for initial Phase 1 results to be announced later this year. Our second quarter cash balance provides sufficient resources and runway necessary to take us through 2008 and proactively move the obesity program forward."
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (or MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
GENAERA CORPORATION
STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
Revenues $2,403 $85 $2,610 $245
Costs and expenses
Research and development 3,089 4,590 6,559 10,750
General and administrative 1,639 1,495 3,071 3,102
4,728 6,085 9,630 13,852
Loss from operations (2,325) (6,000) (7,020) (13,607)
Interest income 338 246 705 486
Loss before income taxes (1,987) (5,754) (6,315) (13,121)
Income tax benefit -- -- 147 --
Net loss $(1,987) $(5,754) $(6,168) $(13,121)
Net loss per share -
basic and diluted $(0.11) $(0.50) $(0.35) $(1.14)
Weighted average shares
outstanding - basic and
diluted 17,449 11,556 17,446 11,511
CONDENSED BALANCE SHEETS
(Unaudited)
(In thousands)
June 30, December 31,
2007 2006
Cash, cash equivalents and investments $26,311 $33,806
Prepaid expenses and other current assets 1,187 629
Fixed assets, net 561 759
Other assets 56 56
Total assets $28,115 $35,250
Current liabilities $2,371 $2,427
Long-term liabilities 66 1,770
Stockholders' equity 25,678 31,053
Total liabilities and stockholders' equity $28,115 $35,250
Source: Genaera Corporation
Mail to Friend Email Story
Alerts
GENR Genaera Corporation Presents New Preclinical Data for Obesity Compound Trodusquemine (MSI-1436) at CBI Conference
7/27/2007
MSI-1436 is an Allosteric, Noncompetitive Inhibitor of PTP-1B
PLYMOUTH MEETING, Pa., July 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Genaera Corporation (Nasdaq: GENR) today announced new data from preclinical studies of trodusquemine (MSI-1436) for the treatment of obesity. Michael McLane, Ph.D., Vice President, Nonclinical Development, presented "Trodusquemine: A Novel Small Molecule for the Treatment of Obesity and Related Metabolic Disorders," during the CBI 3rd Annual Obesity Drug Development Summit, July 26-27 in Arlington, Va.
The presentation summarized results from preclinical studies demonstrating that MSI-1436 is a potent, highly-selective and reversible inhibitor of PTP-1B, an enzyme central to the function of both the leptin and insulin pathways. The mechanism of this inhibition, as indicated by in vitro kinetics, is through binding to a site different from the catalytic site of PTP-1B. The in vitro kinetics demonstrates that MSI-1436 is an allosteric, noncompetitive inhibitor of PTP-1B. Data presented also indicates that MSI-1436 crosses the blood brain barrier and is both centrally and peripherally active. These dual locations of MSI-1436 action make the drug a promising therapeutic candidate for both obesity and type 2 diabetes.
"This new preclinical data continues to support our conclusion that inhibition of PTP-1B is the predominant mechanism of action of MSI-1436 and differentiates it from other drugs currently in development," commented Jack Armstrong, President and Chief Executive Officer of Genaera. "By demonstrating MSI-1436 is an allosteric, noncompetitive inhibitor of PTP-1B, we believe the drug is well-positioned to change the treatment paradigm for obese type 2 diabetics, something we have set out to verify in our ongoing clinical development program."
As previously disclosed, preclinical studies also demonstrate that MSI- 1436 suppresses appetite and causes differential weight loss in a mouse model of diet induced obesity (DIO). In addition, MSI-1436 was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model. MSI-1436 is currently being evaluated in humans in a Phase 1 study for safety and pharmacokinetics in healthy obese volunteers.
About Trodusquemine (MSI-1436)
Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established, validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B), that is central to both insulin and leptin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment of two of the most serious metabolic diseases, obesity and type 2 diabetes. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to address co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
Investor Relations of Genaera Corporation, +1-610-941-5675; or Media, Susan Neath of Porter Novelli Life Sciences, +1-619-849-6007, sneath@pnlifesciences.com, for Genaera Corporation http://www.genaera.com/
Copyright (C) 2007 PR Newswire. All rights reserved
no idea ?
They have a huge holding now.
what is their game?
Why does XMARK keep buying? i dont see too much exciting going on, any thoughts?
>What do you think XMark are doing then? Why would someone spend so much money to accumulate so many shares... They can't be that silly.<
That’s what TELK investors said about Black Bear and look what happened there.
I have no idea what XMark are doing but I sure as heck would not own shares just because of them. Regards, Dew
You mean pick up your change and walk away?
Think I'll try to get some back first with a little trading around my core .
What do you think XMark are doing then?
Why would someone spend so much money to accumulate so many shares .....
They can't be that silly .
>Maybe market feels that we are getting rid of excess unnecessary baggage ...What say you?<
The good news is that management is finally coming clean on Lomucin and Squalamine.
The bad news is that management is still playing from the same rulebook.
Trodusquemine doesn’t have a snowball’s chance in Hell of making it to market and management is well aware of this. Regards, Dew
Funny ,I thought ...OH NO ,we'll get punished for that .
But what the heck...we're up so far today .....
Go figure?
Maybe market feels that we are getting rid of eccess uneccessary baggage ...
What say you?
any way I am glad to see $3 again.
My main hunch is that Xmark is not silly enough to waste millions for nothing....
I have soooo far to go until I break even here after about 4 years of roller coaster ride.
deep
Y'all can stop talking about Lomucin and Squalamine now:
#msg-20970738.
Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
via COMTEX
June 25, 2007
PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Genaera Corporation (Nasdaq: GENR) today announced that data from a preclinical study of trodusquemine (MSI-1436) for the treatment of obesity were presented during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz, Genaera research scientist and lead author of Abstract #1801-P, presented, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."
The poster presentation summarizes results from preclinical studies demonstrating that trodusquemine suppresses appetite and causes differential weight loss in a mouse model of diet-induced obesity (DIO). Data presented also indicates that trodusquemine selectively inhibits PTP-1B, an enzyme central to controlling the function of both the leptin and insulin pathways. In addition, trodusquemine was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model, making trodusquemine a promising therapeutic candidate.
"This preclinical data supports our current Phase 1 clinical strategy for trodusquemine as a treatment for obesity and further reinforces our belief that trodusquemine may also be successful in the treatment of type 2 diabetes," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We believe that, if successful, trodusquemine could be an effective monotherapy able to treat both obesity and type 2 diabetes, and could revolutionize the way these metabolic diseases are treated."
Scientists from Genaera will be available for discussion of the poster today from 12:00 p.m. to 2:00 p.m. Central Time in the Poster Hall at the conference.
For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&Men uID=100
Genaera to Present Preclinical Data on Trodusquemine...
for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
Tuesday June 19, 8:30 am ET
PLYMOUTH MEETING, Pa., June 19 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced that it will present a poster on trodusquemine (MSI-1436), its novel anti-obesity compound, during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22 to 25 in Chicago.
ADVERTISEMENT
The abstract, # 1801-P, is titled, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."
The poster will be available from Saturday, June 23 through Monday, June 25 during the times the General Poster Session is open to conference attendees. Representatives from Genaera will be available to discuss the poster on Sunday, June 24 from 6:15 p.m. to 7:30 p.m. (CT) and on Monday, June 25 from 12:00 p.m. to 2:00 p.m. (CT).
For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&Men uID=1000
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
that's because no one is posting news!
Genaera Regains Full Compliance with NASDAQ Listing Requirements
PLYMOUTH MEETING, Penn., June 5 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that the Company has regained full compliance with listing requirements of the NASDAQ Capital Market. In accordance with Marketplace Rule 4310(c)(4), Genaera was required to achieve a closing bid price of $1.00 or greater for a minimum of 10 consecutive trading days prior to June 22, 2007. On May 30, 2007, the Company received a letter from the NASDAQ Listing Qualifications Staff stating that it had recently demonstrated full compliance with NASDAQ Marketplace Rule 4310(c)(4) and that all related listing matters are closed. As a result, Genaera's common stock will continue to be quoted on the NASDAQ Capital Market provided the Company continues to satisfy the continued listing requirements.
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in- class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes. In addition, we have a value-driven, fully out- licensed partnership with MedImmune for a second core program. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'believe,' 'continue,' 'develop,' 'expect,' 'plan' and 'potential' or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
Hi three Kings
Any basis ?
No news that I can see!
I'm watching...
It may be time???
TK
I can't see anything jump starting us ( I've been in for a very long time )for some time ...
Phase 1 news didn't do much and it's a long way off untill anything in the pipe gets credibility.
So yes chug chug it is ....
still miracles do happen ...I remain optimistic
Closed at $3.00 today--the little train is chugging back--strange--wonder if some news will get it back to the $6 range it should be at? Im out at $4 to get back to even.
Get something done before your summer break guys!!!
Roger--thanks for your service on this tough day for all who have military in their blood.
Make it happen.
PLYMOUTH MEETING, Penn., May 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that MedImmune, Inc. (Nasdaq: MEDI) presented data related to the Interleukin-9 (IL-9) program at the American Thoracic Society (ATS) 2007 Annual Conference held May 18-23 in San Francisco, California. Genaera and MedImmune entered into a collaborative licensing agreement for this program in 2001. MedImmune is conducting research to evaluate the potential to use its fully humanized, developmental stage monoclonal antibody (MAb) targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma. The ATS presentations summarize several preclinical and clinical studies on IL-9 biology and include results from two phase 1 clinical trials to evaluate the safety and pharmacokinetics of the antibody, known as MEDI-528, in healthy adults.
IL-9 is associated with features of asthma including increased airway inflammation, obstruction and hyperresponsiveness, mucin production and mast cell generation. Earlier preclinical study results have demonstrated that inhibition of IL-9 leads to decreased airway inflammation and hyperresponsiveness in animal models. The clinical results presented at ATS indicate that the anti-IL-9 MAb, currently being evaluated in a phase 2 trial in patients with asthma, was well tolerated.
'This first look at human anti-IL-9 data clearly supports the clinical plan MedImmune has undertaken to advance this novel potential treatment for patients with moderate to severe asthma,' said Jack Armstrong, President and Chief Executive Officer of Genaera. 'These data clearly support further study of MEDI-528 in asthma patients. We look forward to our continued relationship with MedImmune and are pleased that the anti-IL-9 antibody is progressing within their respiratory inflammation pipeline.'
In addition to the clinical results described at ATS, results from preclinical studies focused on the role of IL-9 in the pathology of asthma were also presented. These data provide new insight into IL-9's role in mast cell regulation and allergen-induced airway remodeling.
About Anti-IL-9 MAb
IL-9 has been associated with symptoms of asthma including mucous production, lung infiltration of inflammatory cells, and IgE (an immune globulin associated with allergic disease) production. It is one of at least 29 naturally occurring interleukins in the human body
Genaera Corporation Begins Dosing in Phase 1 Trial of Obesity Compound Trodusquemine
PLYMOUTH MEETING, Pa., May 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that dosing of subjects has begun in study MSI-1436C-101, the Phase 1, first-in-man study of trodusquemine (MSI- 1436), its novel anti-obesity compound. MSI-1436 works centrally and peripherally to regulate insulin and leptin receptor signaling through inhibition of its novel target enzyme PTP-1B.
This randomized, vehicle-controlled study, being conducted at a leading obesity clinical research center in Kansas City, is enrolling healthy overweight and obese volunteers to evaluate the safety, tolerability, and pharmacokinetics of ascending single doses of intravenously administered MSI- 1436. This ascending single-dose protocol will initially enroll approximately 35 subjects and is expected to be completed in the second half of 2007.
'We are very pleased that we have met this clinical milestone and can begin to collect human data on this promising compound,' said Jack Armstrong, President and Chief Executive Officer of Genaera. 'What we learn in this first stage of clinical testing will help us understand how MSI-1436 performs in the human body and guide the determination of an optimal therapeutic dose for the larger efficacy trials which follow. The efficiency and quality of this work will be important benchmarks for Genaera moving forward.'
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
About Genaera
Genaera Corporation is a biopharmaceutical company focused on the development of innovative drug candidates in the areas of obesity, metabolic diseases and asthma. The Company is focusing on the development of trodusquemine (MSI-1436) as a treatment for obesity and type 2 diabetes, and the continuation of the anti-IL9 antibody program for the treatment of asthma. Genaera's other compounds include LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; squalamine for the treatment of cancer; and LOCILEX(TM) (pexiganan acetate), a topical antimicrobial.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436). You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'believe,' 'continue,' 'develop,' 'expect,' 'plan' and 'potential' or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
lol yeah but those toes are a heck of a lot funnier!
It's whats in your heart, not what's drawn on your toes...
Good news for Genera and the people fighting obesity
Hey! Where's the happy feet? lol
Weeeeeeeeeeeeee! Good news for Genera!!
FOR IMMEDIATE RELEASE
Contact:
Genaera Corporation Sam Brown Inc. (Media Inquiries)
Investor Relations Mike Beyer
(610) 941-5675 (773) 463-4211
www.genaera.com beyer@sambrown.com
GENAERA CORPORATION INITIATES HUMAN STUDY OF
OBESITY COMPOUND TRODUSQUEMINE
Plymouth Meeting, PA – May 7, 2007 – Genaera Corporation (NASDAQ: GENR) today announced that it has begun enrolling subjects in the first human clinical study of trodusquemine
(MSI-1436) under the Investigational New Drug (IND) application for the obesity compound submitted to the U.S. Food and Drug Administration (FDA) in March 2007. The phase 1 study will enroll healthy overweight and obese volunteers to assess the safety and pharmacokinetics of ascending single doses of trodusquemine. The Company expects to dose the first subjects by the end of May 2007.
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme target for the treatment of diabetes and obesity. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
“We are pleased that FDA has given Genaera the green light to begin testing trodusquemine in humans and that we were able to efficiently execute our clinical program and proceed into the
clinic,” said Jack Armstrong, President and Chief Executive Officer of Genaera. “While the primary endpoint of this first phase 1 study is safety and tolerability, we will be looking for
evidence supporting our pre-clinical observations that rodusquemine induces appetite suppression and weight loss while normalizing glucose metabolism and insulin sensitivity.”
About Genaera Genaera Corporation is a biopharmaceutical company focused on the development of innovative drug candidates in the areas of obesity, metabolic diseases and asthma. The Company is focusing on the development of trodusquemine (MSI-1436) as a treatment for obesity and diabetes, and the continuation of the anti-IL9 antibody program for the treatment of asthma. Genaera’s other compounds include LOMUCIN™, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; squalamine for the treatment of
cancer; and LOCILEX™ (pexiganan acetate), a topical antimicrobial.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera’s programs including trodusquemine (MSI-1436). You may identify some of these forward-looking statements by the use of words in the statements such a “anticipate,” “believe,” “continue,” “develop,” “expect,” “plan” and “potential” or other words of similar meaning. Genaera’s
actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera’s history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the
risk that clinical trials for Genaera’s product candidates, including trodusquemine (MSI-1436), may be delayed or may not be successful; the risk that Genaera may not obtain regulatory
approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera’s reliance on its collaborators, in connection with the development and commercialization of Genaera’s product candidates; market acceptance of Genaera’s products, if regulatory approval
is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera’s filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at
www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera
does not intend (and it is not obligated) to publicly update, revise or correct these forwardlooking statements or the risk factors that may relate thereto.
Yes, many more to cover as we near May 11th
Yes it was....
The shares will have to be turned in...
Before the R/S...
TK
>Considering that you are posting here does that mean you are a fellow investor??<
No—I was long from early 2003 to late 2004 and sold at more than $4. I predicted that GENR would drop the Evizon program more than a year before they actually did.
I have no intention of buying, but I still follow the developments out of curiosity. Regards, Dew
Dew, Considering that you are posting here does that mean you are a fellow investor??
And if so how long have you held GENR?
Are you employed by or contracted by any firms associated with the stock market?
still no word on Astra Zeneca's deal now that medi is out of the picture? when and how will we hear about that?
I made a bundle...
How about you...
TK
>All O'''board...
.60...
.70...
Then the 1.00$$$
<
It seems to be going in the other direction.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
234
|
Created
|
07/17/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |